優(yōu)立替尼|T7005

2篇文獻(xiàn)

價(jià)格	詢價(jià)
包裝	1removed

最小起訂量	1removed
發(fā)貨地	上海
更新日期	2026-05-08

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:優(yōu)立替尼	英文名稱:Ulixertinib
CAS:869886-67-9	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Store at low temperature Pure form: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
純度規(guī)格: 99.86%	產(chǎn)品類別: 抑制劑
貨號(hào): T001\|T7005

Product Introduction

Bioactivity

名稱	Ulixertinib
描述	Ulixertinib (VRT752271) (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC₅₀ of Ulixertinib is less than 0.3 nM for ERK2.
細(xì)胞實(shí)驗(yàn)	A375 cells are cultured in cell media composed of DMEM, 10% (v/v) Foetal Calf Serum and 1% (v/v) L-Glutamine. After harvesting, cells are dispensed into black, 384-well Costar plates to give 200 cells per well in a total volume of 40 μL cell media, and are incubated overnight at 37°C, 90% relative humidity and 5% CO2 in a rotating incubator. Test compounds and reference controls are dosed directly into the cell plates, into the inner 308 wells, using a Labcyte Echo 555 acoustic dispenser. The cells are dosed over a 12 point range from 30 μM down to 0.03 nM in order to calculate compound IC50s, with a total DMSO concentration in the assay of 0.3%. The cell plates are then incubated for 72 hours at 37°C. Cells were fixed and stained by the addition of 20 μL 12% formaldehyde in PBS/A (4% final concentration) and 1:2000 dilution of Hoechst 33342, with a 30 minute room temperature incubation, and then washed with PBS/A. A cell count is performed on the stained cell plates using a Cellomics ArrayScanTM VTI imaging platform. A Day 0 cell plate is also fixed, stained and read to generate a cell count baseline for determining compound cytotoxic effects as well as anti-proliferative effects.(Only for Reference)
激酶實(shí)驗(yàn)	ERK2 Rapidfire Mass Spectrometry Inhibition of Catalysis Assay: MEK U911-activated ERK2 protein is expressed and purified in-house. Enzyme and substrate solutions are made up in assay buffer consisting of 50 mM Tris (pH 7.5), 10 mM MgCl2, 0.1 mM EGTA, 10 mM DTT and 0.01% (v/v) CHAPS. 1.2 nM ERK2 protein is prepared in assay buffer and 10 μL is dispensed into each well of a polypropylene, 384-well plate containing test and reference control compounds. The compound plates had previously been dosed with a 12 point range from 100 μM down to 0.1 nM in order to calculate compound IC50s, with a total DMSO concentration in the assay of 1%. Following a 20 minute pre-incubation of enzyme and compound at room temperature, 10 μL of substrate solution is added consisting of 16 μM Erktide (IPTTPITTTYFFFK) and 120 μM ATP (measured Km) in assay buffer. The reaction is allowed to progress for 20 minutes at room temperature before being quenched by the addition of 80 μl 1% (v/v) formic acid. The assay plates are then run on the RapidFire Mass Spectrometry platform to measure substrate (unphosphorylated Erktide) and product (phosphorylated Erktide) levels.
體外活性	在含有b-RAFV600E突變的A375黑色素瘤細(xì)胞株中，Ulixertinib分別以IC50為4.1/0.14 μM降低磷酸化ERK2（pERK）和下游激酶RSK（pRSK）的水平。同時(shí)，Ulixertinib以IC50為180 nM抑制A375細(xì)胞的增殖。[1]
存儲(chǔ)條件	Store at low temperature Pure form: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 250 mg/mL (576.93 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8 mg/mL (18.46 mM), Solution. Ethanol : 12 mg/mL (27.69 mM), Sonication is recommended.
關(guān)鍵字	VRT-752271 \| VRT 752271 \| Ulixertinib \| Inhibitor \| inhibit \| Extracellular signal regulated kinases \| ERK2 \| ERK \| BVD523 \| BVD 523
相關(guān)產(chǎn)品	Urea \| Lidocaine hydrochloride \| Lactose \| Nisin Z \| Tauroursodeoxycholate \| Gum arabic \| Gluconate Calcium \| Gluconate sodium \| β-Glycerophosphate disodium salt pentahydrate \| Propoxur \| TBHQ \| L-Cysteine
相關(guān)庫(kù)	抑制劑庫(kù) \| 抗癌活性化合物庫(kù) \| 經(jīng)典已知活性庫(kù) \| 已知活性化合物庫(kù) \| 臨床失敗化合物庫(kù) \| 激酶抑制劑庫(kù) \| 抗衰老化合物庫(kù) \| 免疫/炎癥分子化合物庫(kù) \| 疼痛相關(guān)化合物庫(kù) \| 藥物功能重定位化合物庫(kù) \| 抗癌臨床化合物庫(kù) \| 抗癌藥物庫(kù)

關(guān)鍵字：優(yōu)立替尼;VRT752271;BVD-523;TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （14年）	注冊(cè)資本	566.2651萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營(yíng)模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 14年

公司成立：14年
注冊(cè)資本：566.2651萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑，藥物篩選化合物庫(kù)，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤(pán)

店內(nèi)推薦

化合物 PD0325901|T6189

詢價(jià)

恩格列凈|T1766

￥108

卡博替尼|T2586

詢價(jià)